 Naphthylethylureas and naphthylethylthioureas |
| We claim: 1. A method of treating a mammal afflicted with a disorder of the melatoninergic system ... |
|
| Trisubstituted naphthylalkylamides for disorders of the melatoninergic system |
| We claim: 1. A compound of formula (I): ##STR28## in which: R represents hydrogen or a radical ... |
|
| Potent inducers of terminal differentiation and method of use thereof |
| OF THE INVENTION The invention provides a class of compounds having the structure: [R--A]--B--A.... |
|
| Production of propionic acid |
| What is claimed is: 1. A one-step process for the preparation of propionic acid which comprises ... |
|
| 1-Ethyl-1-(alkoxycarbonylethyl)-octahydro-indolo[2,3-a]quinolizines |
| What we claim is: 1. 1.alpha.-Ethyl-1-(sec-butoxycarbonyl-ethyl)-1,2,3,4,6,7,12, 12b.alpha.-... |
|
| Saccharase inhibiting 3,4,5-trihydroxypiperidine derivatives |
| What is claimed is: 1. A 3,4,5-trihydroxypiperidine derivative of the formula ##STR99## or a ... |
|
| Substituted hydroxy pyridones |
| What is claimed is: 1. A compound of the formula ##STR8## where R.sub.1 represents lower alkyl or ... |
|
| Methyl 1-(3,4-dichlorobenzyl)-2,3-dioxoisonipecotate |
| What is claimed: 1. Methyl 1-(3,4-dichlorobenzyl)-2,3-dioxoisonipecotate.
Description:
... |
|
| Tetrazolyl containing naphthyridine 3-carboxamides |
| We claim: 1. A compound of the formula ##SPC5## or the formula ##SPC6## in which R.sub.1 represents ... |
|
| Phosphorus-containing squalene synthetase inhibitors, new intermediates and method |
| What is claimed is: 1. A compound having the structure ##STR41## wherein R.sup.5 is OH or Cl and Q ... |
|
|
Vitamin E orotate and a method of producing the same
| Details |
Inventors: Hasunuma, Kyotaro; Kurokawa, Masahiro; Abe, Takashi;
Assignee: Kanebo Ltd. (Tokyo, JA)
Primary Examiner: Gallagher; R.
Assistant Examiner: Tighe; Anne Marie T.
Attorney, Agent or Firm: Kenyon & Kenyon
Vitamin E orotate which is useful in medicines and cosmetics, is produced by esterifying vitamin E with an orotyl halide or orotic anhydride or with orotic acid in the presence of phosphorous oxychloride. |
|
DETAILED DESCRIPTION What we claim is: 1.
Vitamin E orotate consisting of a tocopheryl moiety selected from .
alpha.
-, .
beta.
-, .
gamma.
- and .
delta.
-tocopheryl groups and an unsubstituted orotyl moiety combined with said tocopheryl moiety through an ester linkage.
2.
Vitamin E orotate as claimed in claim 1, wherein said .
alpha.
-tocopheryl group is selected from dl-.
alpha.
-, d-.
alpha.
- and l-.
alpha.
-tocopheryl groups.
Description:
The present invention relates to vitamin E orotate and a method of producing the same.
The term "vitamin E" used herein refers to .
alpha.
-tocopherol which includes dl-.
alpha.
-, d-.
alpha.
-, and l-.
alpha.
-tocopherols, .
beta.
-tocopherol, .
gamma.
-tocopherol, .
beta.
-tocopherol and mixtures of two or more of the above-mentioned tocopherols.
The .
alpha.
-tocopherol is of the formula: ##SPC1## .
beta.
-TOCOPHEROL AND .
gamma.
-TOCOPHEROL ARE OF FORMULAS SIMILAR TO THAT SHOWN ABOVE EXCEPT BOTH ARE WITHOUT ONE METHYL GROUP.
It is widely known that vitamin E is effective for vasodilation of peripheral blood vessels, normalization of liver functions and muscular functions, the prevention of blood vessel sclerosis and for promoting fertility.
Therefore, when ingested or applied on skin surfaces, vitamin E is very effective for curing chilblains, exudative erythema, frostbite and feeling of cold.
However, vitamin E is not or only negligibly, effective for moisturizing and retarding aging of human skin.
Also, it is known that acetic ester of vitamin E tends to be easily hydrolyzed, and the hydrolyzed compound emits the unpleasant odor of acetic acid.
Further, the acetic ester of vitamin E has a relatively low moisturizing effect on human skin.
Orotic acid (1,2,3,6-tetrahydro-2,6-dioxo-4-pyrimidinecarboxylic acid, uracil-6-carboxylic acid) is of the formula: ##SPC2## And is a pecurser of pyrimidine which is a moiety of nucleic acid and, therefore, has an influence on the metabolism of the nucleic acid.
Also, it has been reported that the orotic acid is the same substance as vitamin 13 which is a factor of animal growth, or an important moiety of vitamin 13
|
| Related patents |
|
|
Treatment of liver dysfunction with 2-amino-6-benzyl-3-ethoxycarbonyl-4,5,6,7-tetrahydro-thieno[2,3-c]pyridi ne hydrochloride
OF THE INVENTION The present invention has been accomplished on the basis of new finding that tinoridine hydrochloride shows highly protective effects on liver injuries ...
|
|
|
Intravitreal medicine delivery
Intravitreal Medicine Delivery Device- First Embodiment The first embodiment of an intravitreal medicine delivery device of the resent invention is identified in FIGS. 1...
|
|
|
Deodorant and antimicrobial dispersions
OF THE INVENTION AND PREFERRED EMBODIMENTS The present invention will next be described more specifically based on preferred embodiments. The deodorant and ...
|
|
|
Process for hypotensive 4-amino-2-(piperazin-1-yl) quinazoline derivatives
OF THE INVENTION As indicated before, the object of the instant invention is to provide a process for the preparation of compounds of formula I, by reaction of a ...
|
|
|
Child-resistant safety belt buckle
Referring to FIG. 1, a push-button safety belt buckle 1 is shown comprising a metal body 2 that is connected to one end 3 of a segment safety belt 4 or harness and a ...
|
|
|
Synthetic compounds and compositions with enhanced cell binding
In one aspect of the present invention, a family of synthetic peptides are provided that mimic the cell binding domain of collagen so that these compounds competitively ...
|
|
|
Substituted fusaric acid derivatives
OF THE PREFERRED EMBODIMENTS The halo-fusaric acid amides of this invention have the formula: ##SPC3## Wherein X represents hydrogen or halogen atom; and Y represents a ...
|
|
|
Preparation of 5,8-methano-5H-benzocyclohepten-10-amines
The subject matter which the applicant regard as their invention is particularly pointed out and distinctly claimed as follows: 1. A process for the preparation of a ...
|
|
|
Preparation of piperidinyl-alkyl-benzamides
I claim: 1. Piperidinyl-alkyl-benzamides having the general formula ##STR5## wherein R is hydrogen, an alkyl group having from 1 to 4 carbon atoms, an alkoxy group ...
|
|
|
Naphthylethylureas and naphthylethylthioureas
We claim: 1. A compound selected from those of formula I: ##STR4## in which: R represents hydrogen or a group OR.sub.3 wherein R.sub.3 represents straight-chained or ...
|
|
|
Vasodialators 
